KR930700134A - 이종 소포 리포좀 - Google Patents
이종 소포 리포좀Info
- Publication number
- KR930700134A KR930700134A KR1019920702302A KR920702302A KR930700134A KR 930700134 A KR930700134 A KR 930700134A KR 1019920702302 A KR1019920702302 A KR 1019920702302A KR 920702302 A KR920702302 A KR 920702302A KR 930700134 A KR930700134 A KR 930700134A
- Authority
- KR
- South Korea
- Prior art keywords
- biologically active
- group
- agent
- liposomes
- encapsulated
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims description 18
- 239000000126 substance Substances 0.000 claims 16
- 150000002632 lipids Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 9
- 229940088623 Biologically Active Substance Drugs 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000003960 organic solvent Substances 0.000 claims 5
- 239000000839 emulsion Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 3
- 239000002220 antihypertensive agent Substances 0.000 claims 3
- 108091006028 chimera Proteins 0.000 claims 3
- 239000012458 free base Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000007762 w/o emulsion Substances 0.000 claims 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 2
- 229940035676 ANALGESICS Drugs 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 229960005337 Lysine Hydrochloride Drugs 0.000 claims 2
- 210000003956 Transport Vesicles Anatomy 0.000 claims 2
- 239000000159 acid neutralizing agent Substances 0.000 claims 2
- 230000000202 analgesic Effects 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 239000002368 cardiac glycoside Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 229960003646 lysine Drugs 0.000 claims 2
- 238000010907 mechanical stirring Methods 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 2
- 108020004084 membrane receptors Proteins 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 150000003017 phosphorus Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001624 sedative Effects 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- 229960005486 vaccines Drugs 0.000 claims 2
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 206010003119 Arrhythmia Diseases 0.000 claims 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 229940097217 CARDIAC GLYCOSIDES Drugs 0.000 claims 1
- 229960004015 Calcitonin Drugs 0.000 claims 1
- 102400000113 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 Daunorubicin Drugs 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 1
- 229940008250 Leuprolide Drugs 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- 229960004338 Leuprorelin Drugs 0.000 claims 1
- 229960001156 Mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 210000004940 Nucleus Anatomy 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N Ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 1
- 229940067631 Phospholipids Drugs 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- 229960005454 Thioguanine Drugs 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 229960003048 Vinblastine Drugs 0.000 claims 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N [(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000011149 active material Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003178 anti-diabetic Effects 0.000 claims 1
- 230000000843 anti-fungal Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 230000002763 arrhythmic Effects 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229910001873 dinitrogen Inorganic materials 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000008282 halocarbons Chemical class 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 230000001077 hypotensive Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003340 mental Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 230000003472 neutralizing Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 150000008103 phosphatidic acids Chemical class 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 239000005871 repellent Substances 0.000 claims 1
- 230000002940 repellent Effects 0.000 claims 1
- -1 spingomyelin Chemical compound 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims 1
- 150000008143 steroidal glycosides Chemical class 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- XVTUQDWPJJBEHJ-KZCWQMDCSA-N tetrastearoyl cardiolipin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)CO[P@@](O)(=O)OCC(O)CO[P@](O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC XVTUQDWPJJBEHJ-KZCWQMDCSA-N 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 150000003611 tocopherol derivatives Chemical class 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- 229930003799 tocopherols Natural products 0.000 claims 1
- 235000019149 tocopherols Nutrition 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 150000003626 triacylglycerols Chemical group 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 238000010586 diagram Methods 0.000 description 1
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1 내지 8도는 이종소포 소낭 또는 리포좀의 제조를 기술하는 도표이다.
Claims (34)
- 동일한 리포좀의 분리된 체임버내에 캡슐화되어 있는 둘 이상의 상이한 물질(이중 하나 이상의 생물학적 활성 물질이다)을 갖는 이종소포 지질 소낭 또는 리포좀.
- (a)하나 이상의 유기 용매중에 용해된 제1지질 성분을 제공하고 캡슐화시킬 제1생물학적 활성 물질을 함유하는 제1 비혼화성 수성 성분을 상기 지질 성분에 가하며; (b)두가지 제1비혼화성 성분으로부터 유중수유액을 형성시키고; (c)하나 이상의 유기 용매중에 용해된 제2지질 성분을 제공하고 캡슐화시킬 제2물질을 함유하는 비혼화성 제2수성 성분을 상기 지질 성분에 가하며; (d)두가지 제2비혼화성 성분으로부터 제2유중수 유액을 형성시키고; (e)제1유중수 유액 및 제2유중수 유액을 합하여 키메릭 유액(chimeric emulsion)을 형성시키며; (f)상기 유기 용매와 비혼화성인 제3 매질중에 단계(e)의 생성물을 이동 및 침지시키고; (g)상기 키메릭 유액을 분산시켜 제1물질을 함유하는 제1수성성분 및 제2의 물질을 함유하는 제2수성 성분의 소적들을 다수 함유하는 용매 소구체를 형성시키며; (h)용매 소구체로부터 유기 용매를 증발시켜 이종소포리포좀을 형성시키는 단계를 포함함을 특징으로 하여, 수성 체임버내에 별도로 캡슐화되어 있는 둘 이상의 상이한 물질(이중 하나 이상이 생물학적 활성 물지이다)을 갖는 이종소포 지질소낭 또는 리포좀을 제조하는 방법.
- 제2항에 있어서, 제1 및 제2지질 성분이 인 지질 또는 여러 종류의 인지질의 혼합물인 방법.
- 제2항에 있어서, 3가지 이상의 비혼화성 수성 성분을 함유하는 3가지 이상의 유중수 유액을 합하여 키메릭 유액을 형성시키는 방법.
- 제2항에 있어서, 제1 및 제2 지질 성분이 동일한 방법.
- 제3항에 있어서, 인지질을 포스파티딜콜린, 카디오리핀, 포스파티딜에탄올아민, 스핀고미엘린, 라이소포스파티딜콜린, 포스파티딜세린, 포스파티딜이노시톨, 포스파티딜글리세롤, 및 포스파티드산으로 이루어진 그룹으로부터 선택하는 방법.
- 제3항에 있어서, 하나 이상의 지질 성분이 순 음하전(들)을 갖는 지질을 함유하는 방법.
- 제3항에 있어서. 하나 이상의 인 지질이 콜레스테롤과의 혼합물로 제공되는 방법.
- 제3항에 있어서, 하나 이상의 인 지질이 스테아릴아민과의 혼합물로 제공되는 방법.
- 제2항에 있어서, 제1 및 제2 물질중 하나 이상이 친유성 생물학적 할성 물질인 방법.
- 제2항에 있어서, 제1 및 제2지질 성분중 하나 이상이 단독의 중성 지질이거나 트리글리세라이드, 식물성유, 동물지방, 토코페롤, 토코페롤 에스테르, 콜레스테릴 에스테르, 및 탄화수소로 이루어진 그룹으로부터 선택된 물질과의 혼합물인 방법.
- 제2항에 있어서, 유기 용매를 에테르, 탄화수소, 할로겐화 탄화수소, 할로겐화 에테르, 에스테르, 및 이의 혼합물로 이루어진 그룹으로부터 선택하는 방법.
- 제2항에 있어서, 하이드로클로라이드를 염산, 라이신 하이드로클로라이드, 히스티딘 하이드로클로라이드 및 이의 혼합물로 이루어진 그룹으로부터 선택하는 방법.
- 제2항에 있어서, 생물학적 활성 물질이 친수성인 방법.
- 제14항에 있어서, 친수성의 생물학적 활성 물질을 인터루킨-2, 사이토신 아라비노사이드, 메토트렉세이트, 5-플로올우라실, 시스플라틴, 플록스우리딘, 멜파란, 메캅토퓨린, 티오구아닌, 티노테파, 빈크리스턴, 빈블라스틴, 스트렙토조신, 류프롤라이드, 인터페론, 칼시토닌, 독소루비신, 다우노루비신, 미톡스안트론, 아마크린, 악티노마이신 및 블레오마이신으로 이루어진 그룹으로부터 선택하는 방법.
- 제2항에 있어서, 두 성분의 유화를 기계적인 교반, 초음파 에너지, 및 노즐 분무로 이루어진 그룹으로부터 선택된 방법을 사용하여 수행하는 방법.
- 제2항에 있어서, 제3수성 성분이 하나 이상의 산-중화제를 함유하는 방법.
- 제17항에 있어서, 산-중화제를 유리-염기 라이신 및 유기-염기 히스티딘으로 이루어진 그룹으로부터 단독으로 또는 혼합물로 선택하는 방법.
- 제2항에 있어서, 제3수성 성분의 이온 강도가 대략 0.05미만인 방법.
- 제17항에 있어서, 제3 수성 성분이 탄수화물 및 아미노산으로 이루어진 그룹으로부터 선택된 용질을 추가로 함유하는 수용액인 방법.
- 제17항에 있어서, 제3수성 성분이 글루코오스, 슈크로오스, 락토오스, 유리-염기 라이신, 및 유리-염기 히스티딘으로 이루어진 그룹으로부터 단독으로 또는 혼합된 형태로 선택된 용질을 함유하는 수용액인 방법.
- 제2항에 있어서, 용매 소구체를 형성시키기 위한 분산 단계를 기계적인 교반, 초음파 에너지, 및 노즐분무로 이루어진 그룹으로부터 선택된 방법을 사용하여 수행하는 방법.
- 제2항에 있어서, 용매의 증발을 제2수성 성분상에 질소 가스를 통과시킴으로써 수행하는 방법.
- 제2항에 있어서, 캠슐화시킬 생물학적 활성 물질을 표1의 조성물로 이루어진 그룹으로부터 선택하는 방법.
- 제2항의 방법에 따라 제조된 이종소포 리포좀.
- 동일한 리포좀의 분리된 체임버내에 캡슐화된 둘 이상의 상이한 물질(이들중 하나 이상은 생물학적 활성물질이고, 상기 물질중 하나 이상은 하이드로클로라이드 존재하에 캡슐화된 것이다)을 함유하는 이종소포 리포좀.
- 제26항에 있어서, 하이드로클로라이드가 염산, 라이신 하이드로클로라이드, 히스티딘 하이드로클로라이드 및 이들의 혼합물로 이루어진 그룹으로부터 선택된 이송소포 리포좀.
- 리포좀의 분리된 체임버내에 캡슐화된 상이한 조성의 둘 이상의 물질(이중 하나 이상은 생물학적 활성물질이며, 상기 물질중 하나 이상은 염산 또는 기타 산 하이드로클로라이드 및 중화제의 존재하에서 캡슐화된 것이다)을 함유하는 이송소포 리포좀.
- 제26항에 있어서, 생물학적 활성 조성물이 표1의 조성물로 이루어진 그룹으로부터 선택된 이종소포 리포좀.
- 제28항에 있어서, 생물학적 활성 조성물이 표1의 조성물로 이루어진 그룹으로부터 선택된 이종소포 리포좀.
- 두가지 상이한 물질(이중 하나 이상은 생물학적 활성 물질이다)이 이종소포 리포좀의 분리된 체임버내에 각각 캡슐화된 물질을 환자에게 투여함을 특징으로 하여, 상기 물질로 환자를 치료하는 방법.
- 제26항 내지 제31항중 어느 한 항에 따르는 물질이 이종소포 리포좀내에 캡슐화되어 있는 둘 이상의 상이한 물질(이중 하나 이상은 생물학적 활성 물질이다)을 환자에게 투여함을 특징으로 하여. 상기 물질로 환자를 치료하는 방법.
- 동일한 리포좀의 분리되 체임버내에 캡슐화되어 있는 둘 이상의 상이한 물질로, 이중 하나 이상이 부정맥 치료제, 천식 치료제. 항생제, 항암제, 당뇨병 치료제, 항진균제, 항히스타민제, 고혈압 치료제, 저혈압 치료제, 구충제, 항바이러스제, 세포 표면 수용기 차단제, 심장 글리코사이드, 호르몬, 면역 요법제, 핵산및 유사체, 단백질 및 당단백질, 진정제 및 진통제, 스테로이드, 정신안정제, 및 백신으로 이루어진 그룹으로부터 선택된 생물학적 활성 물질인 물질을 갖는 이종소포 지질 소낭 또는 리포좀.
- 제2항에 있어서, 생물학적 활성 물질이 부정맥 치료제, 천식 치료제, 항생제, 항암제, 당뇨병 치료제, 항진균제, 항히스타민제, 고혈압 치료제, 저혈압 치료제, 구충제, 항바이러스제, 세포 표면 수용기 차단제, 심장 글리코사이드, 호르몬, 면역 요법제, 핵사 및 유사체, 단백질 및 당단백질, 진정제 및 진통제, 스테로이드, 정신 안정제, 백신으로 이루어진 그룹으로부터 선택된 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49684690A | 1990-03-21 | 1990-03-21 | |
US07/496846 | 1990-03-21 | ||
US7/496,846 | 1990-03-21 | ||
PCT/US1991/001849 WO1991014445A1 (en) | 1990-03-21 | 1991-03-20 | Heterovesicular liposomes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR930700134A true KR930700134A (ko) | 1993-03-13 |
KR100203223B1 KR100203223B1 (ko) | 1999-06-15 |
Family
ID=23974416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920702302A KR100203223B1 (ko) | 1990-03-21 | 1992-09-21 | 이종소포 리포좀 및 이를 제조하는 방법 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0524968B1 (ko) |
JP (1) | JP3461000B2 (ko) |
KR (1) | KR100203223B1 (ko) |
CN (1) | CN1053101C (ko) |
AT (1) | ATE123412T1 (ko) |
AU (1) | AU655177B2 (ko) |
CA (1) | CA2078666C (ko) |
DE (1) | DE69110281T2 (ko) |
DK (1) | DK0524968T3 (ko) |
ES (1) | ES2073164T3 (ko) |
FI (1) | FI104464B (ko) |
IE (1) | IE62772B1 (ko) |
IL (1) | IL97615A (ko) |
NO (1) | NO304576B1 (ko) |
NZ (1) | NZ237464A (ko) |
PT (1) | PT97101B (ko) |
RU (1) | RU2120795C1 (ko) |
SA (1) | SA93130496B1 (ko) |
WO (1) | WO1991014445A1 (ko) |
ZA (1) | ZA911974B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180101234A (ko) * | 2017-03-02 | 2018-09-12 | 단디바이오사이언스 주식회사 | 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3278273B2 (ja) * | 1993-12-17 | 2002-04-30 | キヤノン株式会社 | 薬剤徐放性カプセル |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
ES2306462T3 (es) | 1996-12-13 | 2008-11-01 | Novartis Vaccines And Diagnostics, Inc. | Analisis y separacion de proteinas del factor de crecimiento derivadas de plaquetas. |
US5985214A (en) | 1997-05-16 | 1999-11-16 | Aurora Biosciences Corporation | Systems and methods for rapidly identifying useful chemicals in liquid samples |
AU735588B2 (en) | 1997-09-18 | 2001-07-12 | Pacira Pharmaceuticals, Inc. | Sustained-release liposomal anesthetic compositions |
CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
ES2384094T3 (es) | 1997-11-14 | 2012-06-29 | Pacira Pharmaceuticals, Inc. | Producción de liposomas multivesiculares |
AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
BR9910089A (pt) | 1998-05-01 | 2004-06-08 | Chiron Corp | Composições e antìgenos de neisseria meningitidis |
EP1121437B1 (en) | 1998-10-15 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
ES2310055T3 (es) | 1998-12-16 | 2008-12-16 | Novartis Vaccines & Diagnostic | Quinasa humana dependiente de ciclina (hpnqalre). |
US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
RU2245366C2 (ru) | 1999-04-30 | 2005-01-27 | Чирон С.Р.Л. | Антиген neisseria, кодирующая его нуклеиновая кислота, их использование |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
EP2275552B1 (en) | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
PT2289545T (pt) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Vacina de omv suplementada contra meningococos |
US20020082205A1 (en) | 2000-03-08 | 2002-06-27 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
DE60134275D1 (de) | 2000-06-15 | 2008-07-10 | Novartis Vaccines & Diagnostic | Polynukleotide zur bestimmung von kolonkrebs |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
CA2430379A1 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
AU2002303261A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
US7309783B2 (en) | 2001-05-09 | 2007-12-18 | The University Of Connecticut | Mammalian early developmental regulator gene |
JP3966819B2 (ja) | 2001-05-24 | 2007-08-29 | キム,スーギョン | 毛嚢に存在する新規の第2ケラチノサイト成長因子類似体 |
RU2316591C2 (ru) | 2001-11-09 | 2008-02-10 | Джорджтаун Юниверсити | Новые изоформы ингибитора роста васкулярных эндотелиальных клеток |
ES2312649T3 (es) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
DE60326931D1 (de) | 2002-01-08 | 2009-05-14 | Novartis Vaccines & Diagnostic | In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren |
EP2093233A1 (en) | 2002-03-21 | 2009-08-26 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US7138512B2 (en) | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
US7135324B2 (en) | 2002-09-04 | 2006-11-14 | The University Of Connecticut | Viral recombinases, related articles, and methods of use thereof |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
EP2279746B1 (en) | 2002-11-15 | 2013-10-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
PT2270048E (pt) | 2002-12-24 | 2016-02-10 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
WO2004074321A2 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
US7655231B2 (en) | 2003-02-19 | 2010-02-02 | Pfizer Inc. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
JP4926707B2 (ja) | 2003-08-22 | 2012-05-09 | ダニスコ エイ/エス | 封入化抗菌材料 |
GB2388581A (en) | 2003-08-22 | 2003-11-19 | Danisco | Coated aqueous beads |
SG166768A1 (en) | 2003-12-23 | 2010-12-29 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
PT1736541E (pt) | 2004-03-29 | 2013-01-31 | Galpharma Co Ltd | Nova proteína galectina 9 modificada e sua utilização |
HUE037549T2 (hu) | 2004-04-07 | 2018-09-28 | Rinat Neuroscience Corp | Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával |
PT1789593T (pt) | 2004-07-09 | 2017-04-24 | Henry M Jackson Found Advancement Military Medicine Inc | Formas solúveis de glicoproteína g de vírus hendra |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
EP2298807A3 (en) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
SG157415A1 (en) | 2004-11-23 | 2009-12-29 | Adamas Pharmaceuticals Inc | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
CA2588296A1 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
CN101203529A (zh) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
WO2006121560A2 (en) | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
EP1865981A2 (en) | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e in cancer diagnosis, detection and treatment |
WO2006110581A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
RU2486204C2 (ru) | 2005-07-22 | 2013-06-27 | Уай'З Терапьютикс Ко., Лтд. | Антитела против сd26 и способы их применения |
RS57194B1 (sr) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
EP1988920A1 (en) | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
EP2044120B1 (en) | 2006-06-07 | 2019-01-30 | BioAlliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
WO2008116032A1 (en) | 2007-03-21 | 2008-09-25 | Effat Emamian | Compositions and methods for inhibiting tumor cell growth |
WO2008124176A2 (en) | 2007-04-10 | 2008-10-16 | The Administrators Of The Tulane Educational Fund | Soluble and membrane-anchored forms of lassa virus subunit proteins |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
JP5737944B2 (ja) | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | 間質性膀胱炎の治療 |
RU2528738C2 (ru) | 2007-12-18 | 2014-09-20 | Биоэллаенс К.В. | Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения |
AU2009234389B2 (en) | 2008-04-10 | 2014-08-21 | Cell Signaling Technology, Inc. | Compositions and methods for detecting EGFR mutations in cancer |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
PL2510947T3 (pl) | 2009-04-14 | 2016-09-30 | Kompozycje do immunizacji przeciwko Staphylococcus aureus | |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
SG177533A1 (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens |
CN102770443A (zh) | 2009-07-16 | 2012-11-07 | 诺华有限公司 | 脱毒大肠杆菌免疫原 |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
BR112012013487A2 (pt) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | Composições de amantadina e métodos de uso |
TWI552760B (zh) | 2010-02-24 | 2016-10-11 | 雷那特神經科學股份有限公司 | 拮抗劑抗-il-7受體抗體及方法 |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
SA111320266B1 (ar) | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
US9770414B2 (en) * | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
WO2013028527A1 (en) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions and methods for treating cancer |
SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
BR112014014824A2 (pt) | 2011-12-22 | 2019-09-24 | Rinat Neuroscience Corp | anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
EP2866829B1 (en) | 2012-07-02 | 2017-12-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Paramyxovirus and methods of use |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
JP2015536339A (ja) | 2012-11-09 | 2015-12-21 | ファイザー・インク | 血小板由来増殖因子b特異的抗体ならびにこれらの組成物および使用 |
EP3594244A1 (en) | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
SG11201508264UA (en) | 2013-05-07 | 2015-11-27 | Rinat Neuroscience Corp | Anti-glucagon receptor antibodies and methods of use thereof |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
SG11201600171SA (en) | 2013-08-02 | 2016-02-26 | Pfizer | Anti-cxcr4 antibodies and antibody-drug conjugates |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
IL290488B1 (en) | 2015-04-13 | 2024-03-01 | Pfizer | Therapeutic antibodies and their uses |
US10877045B2 (en) | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
JP7068160B2 (ja) | 2015-07-21 | 2022-05-16 | 武田薬品工業株式会社 | 第XIIa因子のモノクローナル抗体阻害剤 |
US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
NZ739871A (en) | 2015-08-19 | 2022-05-27 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
EP3922645A1 (en) | 2015-09-15 | 2021-12-15 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
JP6661319B2 (ja) * | 2015-09-28 | 2020-03-11 | 小林製薬株式会社 | リポソーム |
EP3365369A1 (en) | 2015-10-23 | 2018-08-29 | Pfizer Inc | Anti-il-2 antibodies and compositions and uses thereof |
WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | 抗pd-1抗体及其治疗用途 |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
BR112018012870A2 (pt) | 2015-12-30 | 2018-12-04 | Adamas Pharmaceuticals Inc | métodos e composições para o tratamento de transtornos relacionados à crise |
EP3405490B1 (en) | 2016-01-21 | 2021-10-20 | Pfizer Inc. | Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses |
AU2018226646A1 (en) | 2017-03-03 | 2019-09-19 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
US20200056190A1 (en) | 2017-03-16 | 2020-02-20 | Pfizer Inc. | Tyrosine prototrophy |
WO2018191548A2 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
WO2018231772A1 (en) | 2017-06-13 | 2018-12-20 | Bostongene Corporation | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
WO2019014418A1 (en) | 2017-07-13 | 2019-01-17 | Massachusetts Institute Of Technology | TARGETING THE HDAC2-SP3 COMPLEX TO ENHANCE SYNAPTIC FUNCTION |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | ANTI-NUCLEOLIN ANTIBODIES |
CA3078460A1 (en) | 2017-10-04 | 2019-04-11 | Opko Pharmaceuticals, Llc | Articles and methods directed to personalized therapy of cancer |
MX2020008184A (es) | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
WO2019152705A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Antibodies specific for cd70 and their uses |
WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
KR20230146098A (ko) | 2018-05-23 | 2023-10-18 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
AU2019274654B2 (en) | 2018-05-23 | 2023-07-20 | Pfizer Inc. | Antibodies specific for CD3 and uses thereof |
JP2022538499A (ja) | 2019-07-03 | 2022-09-02 | ボストンジーン コーポレイション | サンプル調製、サンプルシークエンシング、およびシークエンシングデータのバイアス補正と品質管理のためのシステムならびに方法 |
EP4041308A1 (en) | 2019-10-07 | 2022-08-17 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CA3152623A1 (en) | 2019-10-11 | 2021-04-15 | Richard D. Cummings | Anti-tn antibodies and uses thereof |
EP4093426A1 (en) | 2020-01-24 | 2022-11-30 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
WO2021224850A1 (en) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Mask peptides and masked anti-ptk7 antibodies comprising such |
CN116323668A (zh) | 2020-07-17 | 2023-06-23 | 辉瑞公司 | 治疗性抗体及其用途 |
US20230287455A1 (en) | 2020-07-30 | 2023-09-14 | Pfizer Inc. | Cells Having Gene Duplications and Uses Thereof |
EP4203989A2 (en) | 2020-09-03 | 2023-07-05 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
WO2022120256A2 (en) | 2020-12-04 | 2022-06-09 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US20220372580A1 (en) | 2021-04-29 | 2022-11-24 | Bostongene Corporation | Machine learning techniques for estimating tumor cell expression in complex tumor tissue |
WO2023012627A1 (en) | 2021-08-02 | 2023-02-09 | Pfizer Inc. | Improved expression vectors and uses thereof |
US20230245479A1 (en) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Machine learning techniques for cytometry |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
WO2024015561A1 (en) | 2022-07-15 | 2024-01-18 | Bostongene Corporation | Techniques for detecting homologous recombination deficiency (hrd) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2408387A2 (fr) * | 1975-06-30 | 1979-06-08 | Oreal | Compositions a base de dispersions aqueuses de spherules lipidiques |
CH624011A5 (ko) * | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
CA1237671A (en) * | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
EP0199362A3 (en) * | 1985-04-26 | 1987-10-07 | Massachusetts Institute Of Technology | System and apparatus for delayed and pulsed release of biologically active substances |
FR2591105B1 (fr) * | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide. |
GB8704171D0 (en) * | 1987-02-23 | 1987-04-01 | Clayton Found Res | Multivesicular liposomes |
-
1991
- 1991-03-18 ZA ZA911974A patent/ZA911974B/xx unknown
- 1991-03-18 NZ NZ237464A patent/NZ237464A/en unknown
- 1991-03-19 IE IE91191A patent/IE62772B1/en not_active IP Right Cessation
- 1991-03-20 JP JP50728091A patent/JP3461000B2/ja not_active Expired - Lifetime
- 1991-03-20 AT AT91906733T patent/ATE123412T1/de not_active IP Right Cessation
- 1991-03-20 WO PCT/US1991/001849 patent/WO1991014445A1/en active IP Right Grant
- 1991-03-20 DE DE69110281T patent/DE69110281T2/de not_active Expired - Lifetime
- 1991-03-20 EP EP91906733A patent/EP0524968B1/en not_active Expired - Lifetime
- 1991-03-20 ES ES91906733T patent/ES2073164T3/es not_active Expired - Lifetime
- 1991-03-20 DK DK91906733.0T patent/DK0524968T3/da active
- 1991-03-20 IL IL9761591A patent/IL97615A/en not_active IP Right Cessation
- 1991-03-20 CA CA002078666A patent/CA2078666C/en not_active Expired - Lifetime
- 1991-03-20 AU AU75806/91A patent/AU655177B2/en not_active Ceased
- 1991-03-21 PT PT97101A patent/PT97101B/pt not_active IP Right Cessation
- 1991-03-21 RU SU5053129A patent/RU2120795C1/ru not_active IP Right Cessation
- 1991-03-21 CN CN91102478A patent/CN1053101C/zh not_active Expired - Fee Related
-
1992
- 1992-09-17 NO NO923624A patent/NO304576B1/no unknown
- 1992-09-18 FI FI924193A patent/FI104464B/fi active
- 1992-09-21 KR KR1019920702302A patent/KR100203223B1/ko not_active IP Right Cessation
-
1993
- 1993-04-27 SA SA93130496A patent/SA93130496B1/ar unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180101234A (ko) * | 2017-03-02 | 2018-09-12 | 단디바이오사이언스 주식회사 | 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
KR20180101233A (ko) * | 2017-03-02 | 2018-09-12 | 단디바이오사이언스 주식회사 | 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930700134A (ko) | 이종 소포 리포좀 | |
KR100203223B1 (ko) | 이종소포 리포좀 및 이를 제조하는 방법 | |
KR100241300B1 (ko) | 활성물질의 조절된 방출성을 갖는 소포 | |
US4515736A (en) | Method for encapsulating materials into liposomes | |
RU96113086A (ru) | Везикулы с регулируемым высвобождением активных ингредиентов | |
KR910004580B1 (ko) | 의약용 소입자 에어로졸 리포좀 및 의약용 리포좀-약제 조합물 | |
KR970004907B1 (ko) | 하이드로클로라이드의 존재하에서 캅셀화된 생물학적 활성물질을 함유하는 다소포성 리포좀 | |
EP0706374B1 (en) | Method for preparing liposomes | |
US6171613B1 (en) | Method for producing liposomes with increased percent of compound encapsulated | |
US7179484B2 (en) | Protein-stabilized liposomal formulations of pharmaceutical agents | |
FI119621B (fi) | Multivesikulääristen liposomien valmistus aktiivisten aineiden vapauttamiseksi kontrolloidusti | |
EP1011634B1 (en) | Preparation of pharmaceutical compositions | |
IL97538A (en) | Multilayer liposomes containing guanidino aminoglycosides and their preparation | |
DE2907303A1 (de) | Verfahren zur einkapselung biologisch aktiver substanzen | |
KR100446832B1 (ko) | 장벽을 통한 활성성분의 비침습성 도포 또는 운반용 제제를 제조하기 위한 액체 소적 | |
Weiner | Liposomes as carriers for polypeptides | |
US5173219A (en) | Uniform spherical multilamellar liposomes of defined and adjustable size distribution | |
MXPA00006196A (es) | Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva. | |
US20050142182A1 (en) | Long circulating liposome | |
JPH06345663A (ja) | バンコマイシン含有リポソーム製剤 | |
EP0274219A2 (en) | Interleukin-2-containing liposome composition and method for the production thereof | |
NZ247547A (en) | Process for preparing heterovesicular lipid vesicles or liposomes; vesicles containing a chloride and an active agent |